Capricor Therapeutics vs Celularity
CAPR and CELU side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAPR and CELU compare
Capricor Therapeutics is the larger company, worth 27 times as much as Celularity ($652M against $24.4M).
Celularity scores higher on the StockData Score (7 against 5 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAPR | CELU |
|---|---|---|
| Size and price | ||
| Market cap | $652M | $24.4M |
| Share price | $11.22 | $0.751 |
| Change, 1 year | 102% | −57.6% |
| Change, 5 years | 237% | −98.9% |
| Beta (5Y) | 1.21 | 1.96 |
| Employees | 231 | 115 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.3× |
| P/B | 3.1× | – |
| FCF yield | −20.3% | – |
| Growth | ||
| Revenue growth (TTM) | – | −58.1% |
| Revenue growth, 5Y average | – | 13.2% |
| Profitability | ||
| Gross margin | – | 19.2% |
| Operating margin | – | −264% |
| Net margin | – | −246% |
| Return on equity | −100% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 6.77 (better) | 0.11 |
| Altman Z-score | 0.55 (better) | −16.46 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 67.6% | 6.8% |
| Held by insiders | 1.6% | – |
| Insider net buying, 12 months | −$8.4M | – |
| Short interest, % of float | 32.8% | – |
Go deeper
- CAPR stock overview
- CAPR income statement
- CAPR valuation and score
- CELU stock overview
- CELU income statement
- CELU valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.